




April 12, 2022

Stewardship and Sepsis Cases and discussion

Clash of Goals?



Clash of Goals?




Image: Ministry of Health Singapore





GUIDELINES

SURVIVING SEPSIS CAMPAIGN

SEPSIS

Surviving Sepsis Campaign Guidelines 2021



Surviving Sepsis Campaign Guidelines 2021

For adults with suspected sepsis or septic shock but unconfirmed infection, we recommend continuously re-evaluating and searching for alternative diagnoses and discontinuing empiric antimicrobials if an alternative cause of illness is demonstrated or strongly suspected.

Infection Best Practice Dx Infection

For adults with possible septic shock or a high likelihood for sepsis, we recommend administering antimicrobials immediately, ideally within 1 hour of recognition.

Quality of evidence: Low


Infection Strong Time to Antimicrobials

For adults with possible sepsis without shock, we recommend rapid assessment of the likelihood of infectious versus noninfectious causes of acute illness.


Infection Best Practice Time to Antimicrobials



Right Timing



Right Timing



Surviving Sepsis Campaign Guidelines 2021

For adults with possible sepsis without shock, we suggest a time-limited course of rapid investigation and if concern for infection persists, the administration of antimicrobials within 3 hours from the time when sepsis was first recognized.

Quality of evidence: Very low

Infection Weak Time to Antimicrobials

For adults with a low likelihood of infection and without shock, we suggest deferring antimicrobials while continuing to closely monitoring the patient.

Quality of evidence: Very low

Infection Weak Time to Antimicrobials

For adults with suspected sepsis or septic shock, we suggest against using procalcitonin plus clinical evaluation to decide when to start antimicrobials, as compared to clinical evaluation alone.

Quality of evidence: Very low

Infection Weak Procalcitonin



Surviving Sepsis Campaign Guidelines 2021

For adults with sepsis or septic shock at high risk of MRSA, we recommend using empiric antimicrobials with MRSA coverage over using antimicrobials without MRSA coverage.

Infection

Best Practice

MRSA Coverage

For adults with sepsis or septic shock at low risk of MRSA, we suggest against using empiric antimicrobials with MRSA coverage, as compared with using antimicrobials without MRSA coverage.

Quality of evidence: Low

Infection

Weak

MRSA Coverage

For adults with sepsis or septic shock and low risk for multidrug resistant (MDR) organisms, we suggest against using two gram-negative agents for empiric treatment, as compared to one gram-negative agent.

Quality of evidence: Very low

Infection



Weak

Multidrug Resistant Organisms



What drives duration of therapy?


History, the Solar System, and a Human Hand



MRSA nasal swabs:

If it doesn't grow, just say no

- Retrospective study x2 years, 6 ICUs in a single center



Surviving Sepsis Campaign Guidelines 2021

For adults with sepsis or septic shock and high risk for multidrug resistant (MDR) organisms, we suggest using two antimicrobials with gram-negative coverage for empiric treatment over one gram-negative agent.

Quality of evidence: Very low

Infection Weak Multidrug Resistant Organisms

For adults with sepsis or septic shock, we suggest against using double gram-negative coverage once the causative pathogen and the susceptibilities are known.


Quality of evidence: Very low

Infection Weak Double gram-negative coverage



VMC Sepsis Summary Data: July 13, 2018 – August 15, 2018

Combination Therapy



Gram Negative Isolates
Percent susceptible

Organism	No. of Isolates	Ampicillin	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Ceftriaxone	Gentamicin	Levofloxacin	Nitrofurantoin	Piperacillin/tazo	Trimethoprim/Sulfa	Cefepime	Ertapenem	Meropenem	Minocycline
Acinetobacter species	36						100	97		92	97	86		100	
Citrobacter freundii	62			85		85	89	94	97	89	76		100		
Citrobacter koseri	55			96		96	100	100	93	98	98		100		
Enterobacter aerogenes	72			88		88	100	97	21	82	99		100		
Enterobacter cloacae complex	134			89		90	98	97	48	90	90		98		
Escherichia coli	3540	56	65	94	85*	91	93	79	96	96	78		100		
Klebsiella oxytoca	105		61	90	59*	93	99	97	86	90	96		100		
Klebsiella pneumoniae	562		90	98	95*	98	98	94	37	97	92		100		
Morganella morganii	64			89		95	88	73		92	61		100		
Proteus mirabilis	420	80	90	100	94*	98	85	77		100	70		100		
Providencia rettgeri	11			91		100	91	100		100	100		100		
Providencia stuartii	8			100		100	0	13		100	88		100		
Pseudomonas aeruginosa	337			87			97	77		96		94		92	
Raoultella planticola	10		90	90		90	90	100	100	100	90		100		
Serratia marcescens	54			100		100	98	100		96	100		100		
Stenotrophomonas maltophilia	41							93			95				100

* Urine isolates only



Gram Negative Isolates


Percent susceptible

Organism	No. of Isolates	Ampicillin	Ampicillin/Sulbactam	Aztreonam	Cefazolin	Ceftriaxone	Gentamicin	Levofloxacin	Nitrofurantoin	Piperacillin/tazo	Trimethoprim/Sulfa	Cefepime	Ertapenem	Meropenem	Minocycline
Acinetobacter species	68						97	91		82	91	93		94	
Citrobacter freundii	118			81		77	97	90	97	82	86		100		
Citrobacter koseri	79			100		100	100	99	97	100	100		100		
Enterobacter aerogenes	144			80		76	100	97	24	77	99		99		
Enterobacter cloacae complex	226			79		76	97	96	61	80	87		93		
Escherichia coli	7032	56	63	95	89*	92	93	81	97	97	78		100		
Klebsiella oxytoca	137														
Klebsiella pneumoniae	1005														
Morganella morganii	126														
Proteus mirabilis	801	80	91	98	96*	97	82	74		100	70		100		
Providencia rettgeri	35			97		100	100	97		100	83		100		
Providencia stuartii	18			100		100	0	6		100	91		100		
Pseudomonas aeruginosa	706			84			94	74		86		94		92	
Raoultella planticola	19		89	89		89	95	100	100	100	74		100		
Serratia marcescens	119			100		100	100	97		99	100		100		
Stenotrophomonas maltophilia	42							86			81				100

P. aeruginosa isolates (N = 702)
 one tenth the frequency of *E. coli* isolates (N = 7032)

* Urine isolates only

Duration of Exposure to Antipseudomonal β -Lactam Antibiotics in the Critically Ill and Development of New Resistance



There was a 4% increased risk of new resistance for each additional day of any antipseudomonal β -lactam exposure

4% increased risk of new resistance for each additional day of ANY antipseudomonal β -lactam exposure



Increased risk of **NEW** resistance for each additional day of therapy

Cefepime
n = 5274



8%

**Piperacillin/
tazobactam**
n = 2463



8%

Meropenem
n = 3625



2%

*...When comparing a 7-day course with a 10-day course of therapy, **the 10-day course is associated with a 24% increased risk of new resistance compared with the 7-day course***



Surviving Sepsis Campaign Guidelines 2021

For adults with sepsis or septic shock, we suggest using prolonged infusion of beta-lactams for maintenance (after an initial bolus) over conventional bolus infusion.

Quality of evidence: Moderate

Infection

Weak

Beta-lactams

For adults with sepsis or septic shock, we recommend optimizing dosing strategies of antimicrobials based on accepted pharmacokinetic/pharmacodynamic (PK/PD) principles and specific drug properties.

Infection

Best Practice

Optomizing Antimicrobials



Surviving Sepsis Campaign Guidelines 2021

For adults with sepsis or septic shock, we suggest daily assessment for de-escalation of antimicrobials over using fixed durations of therapy without daily reassessment for de-escalation.

Quality of evidence: Very low

Infection Weak De-escalation of Antibiotics

For adults with an initial diagnosis of sepsis or septic shock and adequate source control, we suggest using shorter over longer duration of antimicrobial therapy.

Quality of evidence: Very low

Infection Weak Duration of Antibiotics


For adults with an initial diagnosis of sepsis or septic shock and adequate source control where optimal duration of therapy is unclear, we suggest using procalcitonin AND clinical evaluation to decide when to discontinue antimicrobials over clinical evaluation alone.

Quality of evidence: Low

Infection Weak Procalcitonin



Stabilize...Diagnose...De-escalate



The New Antibiotic Mantra—"Shorter Is Better"

Brad Spellberg, MD


1254 JAMA Internal Medicine September 2016 Volume 176, Number 9

Disease	Treatment, Days	
	Short	Long
Community-acquired pneumonia	3 – 5	7 – 10
Nosocomial pneumonia	≤ 8	10 – 15
Pyelonephritis	5 – 7	10 – 14
Intraabdominal infection	4	10
Cellulitis	5 – 6	10



VMC Sepsis Summary Data: July 13, 2018 – August 15, 2018

Stewardship Opportunities: De-escalation



Right Allergies


A reported penicillin allergy is associated with:

- Increase time to antibiotic administration
- Increased breadth of antimicrobials administered
- Increased use of 2nd and 3rd line agents
- Increase morbidity
- Increased mortality
- Increased length of stay
- And.....is usually wrong!



Antimicrobial Stewardship & Sepsis:


Balancing prompt & appropriate treatment vs. unnecessary and over-treatment



Incorporating sepsis in the day-to-day workflow

SEPSIS AS A PERCENTAGE OF TOTAL ED ADMISSIONS

N = 893
■ Possible Sepsis



MONTHLY SEPSIS CASES TO REVIEW N = 155




DAILY SEPSIS CASES TO REVIEW N = 6



Antimicrobial Stewardship & Sepsis: **Shift the Balance**

Balancing prompt & appropriate treatment vs. unnecessary and over-treatment



Acknowledgements



- Cameron Buck, MD
- Jennifer Carney, RN
- Thu Nguyen, PharmD
- Washington State Health Association (WSHA) Sepsis & AMS Workgroup
Meg Kilcup, Anjelica Armendariz, Valerie Aussem, Alice Ferguson, Will Hahn, Mary Jo Kelly, John Lynch, Laura Quinnan, Jessica Symank, Liza Vaezi, Julianna Van Enk



Discussion, questions, comments?

